|
GB0218556D0
|
|
Expression system
|
|
GB0209508D0
|
|
Assay methods
|
|
GB0207624D0
|
|
Chemokine and uses thereof
|
|
GB0207623D0
|
|
Crystal structure of g-quadruplex
|
|
GB0206839D0
|
|
Anti-cancer combinations
|
|
GB0206086D0
|
|
Materials and methods relating to the production and maintenance of cell lines
|
|
GB0202871D0
|
|
Assays,methods and means
|
|
GB0130733D0
|
|
Therapeutic compounds and their use in therapy
|
|
AU1622802A
|
|
Substituted stilbenes and their reactions
|
|
GB0130223D0
|
|
Materials and methods relating to the production and maintenance of cell lines
|
|
AU1726702A
|
|
Materials and methods for synthesizing stilbenes
|
|
GB0127602D0
|
|
Materials and methods for modulating t-cell activity
|
|
GB0127344D0
|
|
Assay method
|
|
AU1070002A
|
|
Materials and methods relating to nucleic acid amplification and profiling
|
|
AU9571801A
|
|
N<sup>8</sup>,N<sup>13</sup>-disubstituted quino(4,3,2-KL)acridinium salts as therapeutic agents
|
|
GB0123780D0
|
|
Substituted chalcones as therapeutic agents
|
|
GB0123777D0
|
|
Substituted chalcones as therapeutic agents
|
|
GB0121285D0
|
|
Anti-cancer combinations
|
|
GB0116594D0
|
|
Therapeutic compounds
|
|
GB0111218D0
|
|
Assays methods and means
|
